RaidMAljumailyMD
Oncology • Greenville, NCAssistant Professor, Internal Medicine, The Brody School of Medicine at East Carolina University
Are you Dr. Aljumaily?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 32 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
600 Moye Blvd
LEO Jenkins Cancer Services Ste 3e127
Greenville, NC 27834Phone+1 252-744-2315Fax+1 252-744-3418
Summary
- Dr. Raid Aljumaily, MD is an oncologist in Greenville, North Carolina. He is currently licensed to practice medicine in North Carolina, Texas, and Oklahoma. He is affiliated with ECU Health Medical Center and is an Assistant Professor at The Brody School of Medicine at East Carolina University.
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Baghdad College of MedicineClass of 1993
Certifications & Licensure
OK State Medical License 2014 - 2025
TX State Medical License 2023 - 2025
NC State Medical License 2011 - 2015
MA State Medical License 2008 - 2013
PA State Medical License 2005 - 2008- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2015 May 07
- Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
- Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
- Join now to see all
Publications & Presentations
PubMed
- 531 citationsParadoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockadeZiming Wang, Ethan G. Aguilar, Jesus I. Luna, Cordelia Dunai, Lam T. Khuat
Nature Medicine. 2019-01-01 - 426 citationsAvelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trialManish R. Patel, John Allan Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael Gordon
The Lancet. Oncology. 2018-01-01 - 50 citationsSelective Blockade of Matrix Metalloprotease-14 with a Monoclonal Antibody Abrogates Invasion, Angiogenesis, and Tumor Growth in Ovarian CancerRajani Kaimal, Raid Aljumaily, Sarah L. Tressel, Rutika V. Pradhan, Lidija Covic
Cancer Research. 2013-04-15
